{"id":"W4403833200","doi":"10.1681/asn.2024r76pk0r1","title":"Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Randomized controlled trial; Medicine; Safety profile; Phase (matter); Internal medicine; Urology; Adverse effect; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002167053,0.0001916393,0.002347456,0.0001084987,0.00007784305,0.000007984346,0.000390229,0.0001561135,0.00005414284],"category_scores_gemma":[0.0005513428,0.0001151996,0.001185388,0.0002957086,0.002645561,0.00006679726,0.00009568395,0.0006502816,0.000002526139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002999345,"about_ca_system_score_gemma":0.0002400774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004058063,"about_ca_topic_score_gemma":0.000002587897,"domain_scores_codex":[0.9964221,0.001296165,0.00175029,0.0001911091,0.00008553878,0.0002548362],"domain_scores_gemma":[0.9941314,0.003754168,0.001774071,0.0002447588,0.00008662104,0.000008985003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7768316,0.000541078,0.000001668118,0.000009608846,0.001625432,0.000002412551,0.003831657,0.00003920895,0.2094526,0.0000629269,0.001129275,0.00647246],"study_design_scores_gemma":[0.978974,0.001747363,0.0005786364,0.0001231663,0.0004983833,0.00005700654,0.001841468,0.0001492543,0.00130321,0.0004275974,0.01419077,0.0001091034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9615519,0.03260357,0.0001621181,0.00407324,0.000677674,0.0007949,0.00004555123,0.000008435744,0.00008259472],"genre_scores_gemma":[0.9962058,0.002910529,0.0001218551,0.0005915651,0.00002510792,0.000008633749,0.000008947427,0.00001183391,0.0001157126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2081494,"threshold_uncertainty_score":0.9747677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009869083897193067,"score_gpt":0.267093345491571,"score_spread":0.257224261594378,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}